Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

R926112

Other · developed by Rigel Pharmaceuticals

Phase 2 Most advanced trial (none active)
RIGL Developer
1 Registered trials

What is R926112?

R926112 is an investigational agent studied in seasonal allergic rhinitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Immunology, Respiratory
Developer
Rigel Pharmaceuticals (RIGL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00115089 Phase 2 Rhinitis, Allergic, Seasonal Completed RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rhinitis, Allergic, Seasonal

More from Rigel Pharmaceuticals

Follow RIGL, the company behind R926112

See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RIGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.